Business Description
Arovella Therapeutics Ltd
ISIN : AU0000182784
Compare
Compare
Traded in other countries / regions
ALA.AustraliaE4NA.Germany IPO Date
2021-10-27Description
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.59 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 28.4 | |||||
| Beneish M-Score | -6.58 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -30.7 | |||||
| 3-Year EBITDA Growth Rate | 39.9 | |||||
| 3-Year EPS without NRI Growth Rate | 22.7 | |||||
| 3-Year FCF Growth Rate | 22 | |||||
| 3-Year Book Growth Rate | -45.7 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 71.59 | |||||
| 9-Day RSI | 69.18 | |||||
| 14-Day RSI | 65.49 | |||||
| 6-1 Month Momentum % | 14.29 | |||||
| 12-1 Month Momentum % | 213.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.37 | |||||
| Quick Ratio | 2.37 | |||||
| Cash Ratio | 2.18 | |||||
| Days Sales Outstanding | 483.19 | |||||
| Days Payable | 21413.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -71.7 | |||||
| Shareholder Yield % | -4.86 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 34.29 | |||||
| Operating Margin % | -30608.57 | |||||
| Net Margin % | -29222.86 | |||||
| FCF Margin % | -18072.73 | |||||
| ROE % | -274.68 | |||||
| ROA % | -184.18 | |||||
| ROIC % | -1073.81 | |||||
| ROC (Joel Greenblatt) % | -7309.29 | |||||
| ROCE % | -274.12 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 150 | |||||
| PB Ratio | 50 | |||||
| EV-to-EBIT | -15.06 | |||||
| EV-to-Forward-EBIT | -9.51 | |||||
| EV-to-EBITDA | -15.26 | |||||
| EV-to-Forward-EBITDA | -8.66 | |||||
| EV-to-Revenue | 4403.11 | |||||
| EV-to-Forward-Revenue | 4.99 | |||||
| EV-to-FCF | -23.91 | |||||
| Price-to-Median-PS-Value | 9 | |||||
| Earnings Yield (Greenblatt) % | -6.64 | |||||
| FCF Yield % | -4.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arovella Therapeutics Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.022 | ||
| EPS (TTM) (€) | -0.008 | ||
| Beta | -0.28 | ||
| Volatility % | 75.3 | ||
| 14-Day RSI | 65.49 | ||
| 14-Day ATR (€) | 0.002565 | ||
| 20-Day SMA (€) | 0.080675 | ||
| 12-1 Month Momentum % | 213.73 | ||
| 52-Week Range (€) | 0.021 - 0.116 | ||
| Shares Outstanding (Mil) | 1,050.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arovella Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arovella Therapeutics Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Arovella Therapeutics Ltd Frequently Asked Questions
What is Arovella Therapeutics Ltd(FRA:E4NA)'s stock price today?
The current price of FRA:E4NA is €0.09. The 52 week high of FRA:E4NA is €0.12 and 52 week low is €0.02.
When is next earnings date of Arovella Therapeutics Ltd(FRA:E4NA)?
The next earnings date of Arovella Therapeutics Ltd(FRA:E4NA) is 2025-02-28 Est..
Does Arovella Therapeutics Ltd(FRA:E4NA) pay dividends? If so, how much?
Arovella Therapeutics Ltd(FRA:E4NA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers